Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized 52 week treatment double-blind, triple-dummy parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma

Trial Profile

A multicenter randomized 52 week treatment double-blind, triple-dummy parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol/mometasone (Primary) ; Mometasone; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms PALLADIUM
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals

Most Recent Events

  • 25 Jul 2022 Results of post-hoc analysis assessing efficacy and safety of IND/MF versus SAL/FLU in Asian patients with inadequately controlled asthma from two (PALLADIUM and IRIDIUM) published in the Journal of Asthma
  • 24 Jan 2022 A review outlining the unique strategy used in the accelerated development of IND/GLY/MF that combined various approaches comprising data from 3 study (QUARTZ and PALLADIUM evaluated IND/MF while IRIDIUM and ARGON evaluated IND/GLY/MF) published in the Advances in Therapy
  • 22 May 2021 Results (n=698) of pooled analysis from 2 trials (PALLADIUM and IRIDIUM) assessing the population pharmacokinetic (popPK) analysis of Indacaterol/Glycopyrronium/Mometasone Furoate and estimate the effect of covariates on their pharmacokinetics in patients with asthma, published in the European Journal of Drug Metabolism and Pharmacokinetics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top